Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05926232
NCT05926232AvailableNot Applicable

Expanded Access for Repotrectinib

Bristol-Myers Squibb0 sitesStarted: July 3, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Available
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is an expanded access designed to provide access to Repotrectinib for eligible participants.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Bristol-Myers Squibb
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

No Longer Available
Not Applicable
Expanded Access for Relatlimab
NCT05170659Bristol-Myers Squibb
No Longer Available
Not Applicable
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From CerdulatinibRelapsed/Refractory Chronic Lymphocytic LeukemiaNon-hodgkin's Lymphoma
NCT04757259Alexion Pharmaceuticals, Inc.
No Longer Available
Not Applicable
Expanded Access for Abatacept
NCT05170672Bristol-Myers Squibb
No Longer Available
Not Applicable
Expanded Access to Rovalpituzumab TesirineSmall Cell Lung Cancer
NCT03503890AbbVie
Available
Not Applicable
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataIdiopathic Arthritis (Including sJIA, pJIA, or JPsA)
NCT04159597AbbVie
Expanded Access for Repotrectinib | Clinical Trial